Combination Chemotherapy in Treating Patients With Colorectal Cancer

This study has been completed.
Eastern Cooperative Oncology Group
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: August 3, 2000
Last updated: December 26, 2009
Last verified: February 2007

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if the effectiveness of irinotecan combined with fluorouracil in treating colorectal cancer varies depending on the patient's racial background.

PURPOSE: Phase III trial to study the effectiveness of irinotecan combined with fluorouracil in treating patients from different racial backgrounds who have colorectal cancer that is advanced, recurrent, metastatic or has not responded to treatment with fluorouracil.

Condition Intervention Phase
Colorectal Cancer
Drug: FOLFIRI regimen
Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics in 5-Fluorouracil Refractory Colorectal Cancer: A Population Pharmacokinetic/Pharmacodynamic Study of CPT-11

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: July 2000
Detailed Description:


  • Determine the interracial differences in the pharmacokinetics of irinotecan in combination with fluorouracil in terms of SN-38 glucuronidation and biliary index, and gastrointestinal (GI) toxicity in patients with metastatic, locally advanced, or recurrent colorectal cancer.
  • Determine if there is a significant relationship between UGT1A1 genotype (promoter and/or coding region mutation) and CYP3A4 promoter genotype, vs GI toxicity, bone marrow toxicity, and pharmacokinetics of irinotecan in this patient population.

OUTLINE: Patients are stratified according to race (Asian or Pacific Islander vs black vs Hispanic vs white).

Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 400 patients (100 per stratum) will be accrued for this study within 3 years.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the colon or rectum

    • Metastatic, locally advanced, or recurrent disease
  • Patients must have at least 2 generations (parents and grandparents) who belong to one of the following racial groups:

    • Asian or Pacific Islander (e.g., China, Japan, Korea, the Philippine Islands, or Samoa)
    • Black (originating from the black racial groups of Africa)
    • Hispanic (originating from Mexico, Puerto Rico, Cuba, Central or South America, or other Spanish culture)
    • White (originating from the peoples of Europe, North Africa, or the Middle East)
  • No patients with parents or grandparents of mixed race or race other than that of the patient



  • Not specified

Performance status:

  • CTC 0-2

Life expectancy:

  • Not specified


  • Granulocyte count at least 1,500/mm3
  • Platelet count at least 100,000/mm3


  • Bilirubin no greater than 1.5 mg/dL
  • AST no greater than 3 times upper limit of normal


  • Creatinine no greater than 1.5 mg/dL


  • Not pregnant or nursing
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • Prior adjuvant fluorouracil allowed if relapse occurred at least 6 months after completion of fluorouracil
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
  • No prior irinotecan
  • No other concurrent chemotherapy

Endocrine therapy:

  • No concurrent hormones except steroids for adrenal failure, hormones for nondisease related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic
  • No concurrent prednisone


  • At least 4 weeks since prior radiotherapy (except to bone or soft tissue involving less than 25% of bone marrow)
  • No concurrent radiotherapy


  • At least 4 weeks since prior major surgery


  • No concurrent phenobarbital, valproate, or cyclosporine
  • None of the following concurrently during first course of therapy:

    • Macrolide antibiotics (e.g., azithromycin, erythromycin, clarithromycin, troleandomycin, dapsone)
    • Azole antibiotics (e.g., fuconazole, miconazole, itraconazole, ketoconazole)
    • Triazobenzodiazepines (e.g., alprazolam, midazolam, triazolam)
    • Antidepressants (e.g., fluoxetine, setraline hydrochloride, fluoxamine, nefazodone hydrochloride)
    • Quinolone antimicrobials (e.g., ciprofloxacin, ofloxacin)
    • Imidazole antibiotics (e.g., clotrimazole)
    • Anti-ulcer medications (e.g., omeprazole, lansoprazole)
    • Ethinyl estradiol
    • Diltiazem
    • Cimetidine hydrochloride
    • Cisapride
    • Terfenadine
    • Rifampin
    • Glucocorticoids
    • Antiepileptics
    • Grapefruit juice
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00006103

Sponsors and Collaborators
Cancer and Leukemia Group B
Eastern Cooperative Oncology Group
Study Chair: Brian Leyland-Jones, MD McGill Cancer Centre at McGill University
Study Chair: Sridhar Mani, MD Albert Einstein College of Medicine of Yeshiva University
  More Information

Additional Information:
No publications provided Identifier: NCT00006103     History of Changes
Other Study ID Numbers: CDR0000068113, CLB-9864, E-C9864
Study First Received: August 3, 2000
Last Updated: December 26, 2009
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage III colon cancer
stage IV colon cancer
stage III rectal cancer
stage IV rectal cancer
recurrent colon cancer
recurrent rectal cancer
adenocarcinoma of the colon
adenocarcinoma of the rectum

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors processed this record on July 01, 2015